|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.370 USD | -1.25% |
|
-8.53% | -31.79% |
| Dec. 18 | Annovis announces open-label extension study for Parkinson's disease patients | RE |
| Dec. 18 | Annovis Bio, Inc. Announces Open-Label Extension Study for Parkinson's Disease Patients | CI |
| Capitalization | 63.61M 53.61M 49.07M 46.62M 86.44M 5.77B 89.36M 566M 226M 2.78B 239M 234M 9.75B | P/E ratio 2025 * |
-1.84x | P/E ratio 2026 * | -1.72x |
|---|---|---|---|---|---|
| Enterprise value | 46.61M 39.28M 35.95M 34.16M 63.34M 4.23B 65.48M 415M 166M 2.03B 175M 171M 7.15B | EV / Sales 2025 * |
-
| EV / Sales 2026 * | - |
| Free-Float |
56.36% | Yield 2025 * |
-
| Yield 2026 * | - |
| 1 day | -1.25% | ||
| 1 week | -8.53% | ||
| Current month | -12.59% | ||
| 1 month | -31.59% | ||
| 3 months | +11.85% | ||
| 6 months | -16.31% | ||
| Current year | -31.79% |
| 1 week | 2.29 |  | 2.62 |
| 1 month | 2.29 | | 3.61 |
| Current year | 2.29 | | 4.14 |
| 1 year | 1.11 | | 5.5 |
| 3 years | 1.11 | | 23.89 |
| 5 years | 1.11 | | 132 |
| 10 years | 1.11 | | 132 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 74 | 2008-04-30 | |
Mark Guerin
DFI | Director of Finance/CFO | 57 | 2025-09-24 |
Melissa Gaines
CTO | Chief Tech/Sci/R&D Officer | - | 2022-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 2008-04-30 | |
Michael Hoffman
CHM | Chairman | 75 | 2015-01-06 |
Claudine Bruck
BRD | Director/Board Member | 70 | 2014-12-31 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -4.43% | 0% | 293,477 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.25% | -8.53% | -6.35% | -88.10% | 63.61M | |
| -1.16% | -2.34% | +13.14% | +100.74% | 51.64B | |
| +0.78% | +7.97% | +74.30% | +13.78% | 43.87B | |
| -0.78% | -3.68% | +83.79% | +640.44% | 31.68B | |
| +0.18% | +0.04% | -4.97% | -23.91% | 27.33B | |
| +3.45% | +11.95% | +89.91% | -35.86% | 21.18B | |
| -2.92% | -6.25% | +37.09% | -30.90% | 19.02B | |
| +0.18% | +9.06% | +141.59% | - | 13.04B | |
| -0.47% | +4.26% | +62.97% | +136.40% | 12.45B | |
| -0.84% | -0.01% | +29.98% | +141.07% | 11.57B | |
| Average | -0.28% | +0.65% | +52.14% | +94.85% | 23.18B | |
| Weighted average by Cap. | -0.18% | +0.93% | +51.95% | +125.32% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -27.76M -23.4M -21.41M -20.35M -37.72M -2.52B -39M -247M -98.59M -1.21B -104M -102M -4.26B | -46.08M -38.83M -35.54M -33.77M -62.61M -4.18B -64.73M -410M -164M -2.01B -173M -169M -7.06B |
| Net Debt | -17M -14.33M -13.11M -12.46M -23.1M -1.54B -23.88M -151M -60.38M -742M -63.76M -62.45M -2.61B | -174M -146M -134M -127M -236M -15.77B -244M -1.55B -617M -7.58B -652M -638M -26.64B |
Employees
12
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-02-11 | 2.360 $ | -1.67% | 196,623 |
| 26-02-10 | 2.400 $ | -3.61% | 247,387 |
| 26-02-09 | 2.490 $ | 0.00% | 301,118 |
| 26-02-06 | 2.490 $ | +2.05% | 550,923 |
| 26-02-05 | 2.440 $ | -5.43% | 345,612 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.400USD
Average target price
13.75USD
Spread / Average Target
+472.92%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ANVS Stock
Select your edition
All financial news and data tailored to specific country editions
